DNA repair pathways as targets for cancer therapy

By Thomas Helleday, E. Petermann, Cecilia Lundin, B. Hodgson, Ricky A. Sharma. Nature Reviews. Cancer, 2008

1,734 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/40226b563e4509b5ef57b1417e8c92ce5a67d14b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Thomas Helleday
2. Stephen P. Jackson
3. J. Bartek
4. Pingkun Zhou
5. Ruixue Huang
6. Arul M. Chinnaiyan
7. Michael P. Hay
8. William R. Wilson

In Oncology

1. Stephen P. Jackson
2. J. Bartek
3. Thomas Helleday
4. Yosef Shiloh
5. J. Lukas
6. P. Jeggo
7. Yves Pommier

In Pathology and Forensic Medicine

1. J. Bartek
2. Stephen P. Jackson

Citations in the corpus

• Mechanisms of Multidrug Resistance in Cancer Chemotherapy (2020, background): “In vitro studies have demonstrated that 5-fluoro-2-deoxycytidine and the cytidine analog, decitabine, can reverse this hypermethylation and increase cell sensitivity to cisplatin via restoring MMR functionality [96,97].”
• Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements☆ (2017, background): “Upon exposure to IR, several types of DNA lesions, such as single strand breaks (SSBs), double strand breaks (DSBs), and DNA base modifications, are produced [109].”
• Strategies to improve radiotherapy with targeted drugs (2011, background): “Although some tumours show upregulation of repair proteins, others are often defective in DNA repair, whereas normal tissues are proficien”
• PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination (2009, background): “Inhibition of PARP1 is synthetic lethal with defects in homologous recombination (HR) and is currently being tested as a monotherapy for heritable breast and ovarian cancers deficient in the BRCA1 or BRCA2 genes (Bryant et al, 2005; Farmer et al, 2005; Helleday et al, 2008).”
• Drug resistance and combating drug resistance in cancer (2019, background): “The DNA damage response (DDR) of affected cells to the anticancer drugs may result in reduced efficacy of the drugs by DNA lesion repairs, leading to drug resistance[80].”
• DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy (2021, background): “Notably, HR repair pathway deficiency has been observed in some cancers.(523,524) HRdeficiency caused cancer cells to become sensitized to chemoand radio-therapeutic agents, suggesting that HR deficiency is a valuable pathway to improve radiotherapy resistance.”
• The DNA-damage response in human biology and disease (2009, background): “It has therefore been speculated that DDR inhibition might enhance the effectiveness of radiotherapy and DNA-damaging chemotherapies; and indeed, various DDR-inhibitory drugs are in pre-clinical and clinical development to test this premise 87,88 .”
• Integrative Clinical Genomics of Metastatic Cancer (2017, positive): “Mutations in DNA repair pathways have therapeutic implications; hypermutated tumors may respond to immune checkpoint inhibitors 42 , while HR deficiency could suggest sensitivity to PARP inhibitors 42,43 .”
• Targeting hypoxia in cancer therapy (2011, background): “Although the DNA replication fork can be considered the most successful chemotherapy target to dat”